Gradient-Boosting Algorithm for Microwave Breast Lesion Classification-SAFE Clinical Investigation.

Janjic A., Akduman I., Cayoren M., Bugdayci O., Aribal M. E.

Diagnostics (Basel, Switzerland), cilt.12, sa.12, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 12
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3390/diagnostics12123151
  • Dergi Adı: Diagnostics (Basel, Switzerland)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, INSPEC, Directory of Open Access Journals
  • Anahtar Kelimeler: microwave breast imaging (MBI), SAFE, breast lesion classification, machine learning, DIELECTRIC-PROPERTIES, BIOLOGICAL TISSUES, LARGE-SCALE, DENSITY, RISK, RADIOWAVE, PAIN
  • Marmara Üniversitesi Adresli: Evet

Özet

(1) Background: Microwave breast imaging (MBI) is a promising breast-imaging technology that uses harmless electromagnetic waves to radiate the breast and assess its internal structure. It utilizes the difference in dielectric properties of healthy and cancerous tissue, as well as the dielectric difference between different cancerous tissue types to identify anomalies inside the breast and make further clinical predictions. In this study, we evaluate the capability of our upgraded MBI device to provide breast tissue pathology. (2) Methods: Only patients who were due to undergo biopsy were included in the study. A machine learning (ML) approach, namely Gradient Boosting, was used to understand information from the frequency spectrum, collected via SAFE, and provide breast tissue pathology. (3) Results: A total of 54 patients were involved in the study: 29 of them had benign and 25 had malignant findings. SAFE acquired 20 true-positive, 24 true-negative, 4 false-positive and 4 false-negative findings, achieving the sensitivity, specificity and accuracy of 80%, 83% and 81%, respectively. (4) Conclusions: The use of harmless tissue radiation indicates that SAFE can be used to provide the breast pathology of women of any age without safety restrictions. Results indicate that SAFE is capable of providing breast pathology at a high rate, encouraging further clinical investigations.